Clinical trial Recruiting at 3 sites Interventional Ages 18 to 99

Understanding ADHD and addiction in patients

Official title: Addictions and Attention Deficit Disorder With or Without Hyperactivity

Run by Nantes University Hospital · NCT06232226 · Data updated 2026-11-12

This study is trying to learn more about how ADHD and addiction happen together in people by collecting information from patients over a year to see how well treatments work.

Quick facts

Study typeInterventional
Ages18 Years to 99 Years
SexAll
Enrollment80 (estimated)
SponsorNantes University Hospital
Academic / other
Locations3 sites (Nantes, Loire-Atlantique and 2 other locations)
StatusRecruiting
StartedApril 11, 2024
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedApril 17, 2026
Trial IDNCT06232226 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are individuals aged over 15 years with a recent diagnosis of ADHD and confirmed addictive disorders who have not yet started treatment with methylphenidate.

Probably not a fit

Patients with higher cognitive disorders or those unable to participate in the required visits will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on collecting detailed sociodemographic, clinical, and neuropsychological data from patients diagnosed with both Attention Deficit Hyperactivity Disorder (ADHD) and addiction. Participants will undergo two visits: one for initial evaluation and another after 12 months. Each visit will include structured clinical interviews and neuropsychological assessments conducted by trained professionals. The aim is to enhance understanding of the co-occurrence of these conditions and the effectiveness of treatment approaches.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies for patients dealing with both ADHD and addiction.

How similar studies have gone: While studies on ADHD and addiction exist, this specific approach of systematic data collection in a cohort is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria :

* Patients aged over 18 years
* For whom a diagnosis of ADHD has been confirmed less than 12 weeks ago
* For whom the diagnosis of one or more addictive disorder(s) (substance use disorder or behavioral addiction) has been confirmed
* Meeting the indication for treatment with MPH according to European recommendations (Kooij et al., 2019)
* For patients who can actually benefit from MPH: who have not yet started taking MPH
* Social security affiliates

Exclusion Criteria :

* Presenting disorders of higher cognitive functions (at the discretion of the referring clinician or the investigator making the inclusion), making data collection impossible
* Presenting difficulties in reading or writing the French language making data collection impossible
* Unable to commit to being available for the 2 visits planned as part of the cohort
* Under guardianship or legal protection
* Patients who have used psychoactive substances within 12 hours prior to their visit

Where it's running

  • Nantes University Hospital
    Nantes, Loire-Atlantique, France
    Recruiting
  • CHRU de Brest
    Brest, France
    Recruiting
  • CHRU de Tours
    Tours, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.